1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Vifor Pharma AG
  6. Summary
    VIFN   CH0364749348

VIFOR PHARMA AG

(VIFN)
  Report
Delayed Swiss Exchange  -  05/18 11:30:15 am EDT
178.75 CHF   +0.42%
05/12Update on the timeline for Vifor Pharma tender offer
BU
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
04/29VIFOR PHARMA AG : Ex-dividend day for final dividend
FA
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
177.8(c) 178.2(c) 179(c) 178(c) 178.75(c) Last
108 877 21 017 124 137 189 917 78 288 Volume
+1.98% +0.22% +0.45% -0.56% +0.42% Change
More quotes
Estimated financial data (e)
Sales 2022 2 010 M 2 025 M 2 025 M
Net income 2022 315 M 317 M 317 M
Net cash position 2022 639 M 644 M 644 M
P/E ratio 2022 40,7x
Yield 2022 1,19%
Sales 2023 2 272 M 2 289 M 2 289 M
Net income 2023 376 M 379 M 379 M
Net cash position 2023 1 021 M 1 029 M 1 029 M
P/E ratio 2023 33,3x
Yield 2023 1,21%
Capitalization 11 551 M 11 636 M 11 636 M
EV / Sales 2022 5,43x
EV / Sales 2023 4,63x
Nbr of Employees 2 200
Free-Float 72,2%
More Financials
Company
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject... 
Sector
Pharmaceuticals
Calendar
08/04Earnings Release
More about the company
Ratings of Vifor Pharma AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about VIFOR PHARMA AG
05/12Update on the timeline for Vifor Pharma tender offer
BU
05/11Australia shares slide as U.S. inflation data fuels slowdown woes
RE
04/29VIFOR PHARMA AG : Ex-dividend day for final dividend
FA
04/28Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruri..
AQ
04/2694th Vifor Pharma Group Annual General Meeting
BU
04/26Vifor Pharma Ag Announces Board Changes
CI
04/26Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022
CI
04/20CSL Prices $4 Billion of Bonds in US Debt Market
MT
04/20PAUL RAMSAY : KKR-led group offers record $14.8 billion bid for Australia's Ramsay Health
RE
04/04Vifor Pharma Reports Long-Term Potassium Control from Phase 3b Trial for Veltassa
MT
04/04DIAMOND TRIAL : Veltassa® enables patients to achieve long-term potassium control and opti..
BU
04/04Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial
CI
03/30VIFOR PHARMA AG(SWX : VIFN) dropped from Swiss Performance Index (Price Return)
CI
03/28Australia's CSL Closes Public Tender Offer for Vifor Pharma
MT
03/28Publication of definitive end result for Vifor Pharma tender offer
BU
More news
News in other languages on VIFOR PHARMA AG
05/16BOLSA DE MADRID : Aterrizaje brusco en China
05/16Atterrissage brutal en Chine
05/16AVIS D'ANALYSTES DU JOUR : Michelin, Valeo, Ahold, SMA Solar, Sartorius, Orpea, Cosmo, Car..
05/12La reprise de Vifor pourrait ne pas être bouclée d'ici fin juin
05/12Abschluss der Vifor-Übernahme durch CSL verzögert sich
More news
Analyst Recommendations on VIFOR PHARMA AG
More recommendations
Chart VIFOR PHARMA AG
Duration : Period :
Vifor Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 178,00 CHF
Average target price 157,63 CHF
Spread / Average Target -11,4%
EPS Revisions
Managers and Directors
Shah Abbas Hussain Chief Executive Officer
Alexandros Sigalas Chief Financial Officer
Jacques Theurillat Chairman
Klaus Henning Jensen Chief Medical Officer
Frédéric Zwahlen Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
VIFOR PHARMA AG9.71%11 636
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868